Beyond Cells announced that it will issue 8,037,600 common shares at a price of KRW 500 for gross proceeds of KRW 4,018,800,000 on September 15, 2020. The transaction will involve participation from returning investor Amicogen, Inc. (KOSDAQ:A092040). Post completion of the transaction, the investor will hold 100% stake in the company through 8,037,600 issued shares. The transaction will take place through capital increase. The transaction is expected to close on December 31, 2022. The transaction has been approved by the board of directors of the investor.